Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028?
RégulationOne-OffTechHealth & MedicineEquities1aManifold MarketsSans KYCDonnées de résolution vérifiéesAssez bien calibréPrévision communautaire actuelleOui 70.2%
Prévisionnistes
4
Type de question
binary
Méthodologie
Play-money forecasting platform
Type de source
Prévision
Données du marché
Mis à jour il y a 3 heures
Obsolète6 août 26, 04:06 UTC31 déc. 27, 23:59 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
Will Gustavo Petro face a criminal trial before January 1, 2027?
Manifold MarketsWill the VLA15 Lyme Disease vaccine "pass" its phase 3 human trial?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill Anthropic’s valuation hit __ by September 30?
PolymarketWill OpenAI's valuation hit __ by September 30?
PolymarketAnthropic’s valuation end of October 2026?
PolymarketRègles
Will BGE-102 significantly reduce hsCRP in BioAge's Phase 2 QUELL-CV trial?
- BGE-102 is a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor discovered by BioAge Labs, Inc. (Nasdaq: BIOA).
- NLRP3 drives age-related chronic inflammation implicated in cardiovascular disease, metabolic disorders, and neurodegenerative conditions; BioAge has said its discovery platform nominated NLRP3 from analysis of human aging cohorts in which lower NLRP3 activity tracked with greater longevity (Aug 15, 2025).
- The company has also stated that its compounds engage a binding site and mechanism distinct from other NLRP3 inhibitors in development, with a composition-of-matter patent covering that site issued in January 2026 (Jan 12, 2026).
- Cardiovascular risk reduction is the lead indication.
- This market concerns the QUELL-CV primary endpoint only.
Marchés ouverts
RegulationPOLYMARKETClarity Act (H.R.3633) signed into law in 2026?
- No+2.0pt86%
- Yes-2.0pt14%
- Volume total
- 12,5 M €
- Volume 24h
- 248,7 k €
KALSHIWill the Clarity Act become law?
- Before Oct 1, 2027-14.0pt40%
- Before Jan 1, 2028-15.0pt38%
- Before Jul 1, 2027-15.0pt32%
+7 résultats de plus
POLYMARKETAnthropic IPO by which date?
- December 31,+3.0pt90%
- December 15,86%
- November 30,-1.0pt84%
+7 résultats de plus
- Volume total
KALSHIWhen will Anthropic officially announce an IPO?
- Before Apr 1, 2027+5.0pt97%
- Before Jan 1, 2027+1.0pt96%
- Before Mar 1, 2027-1.0pt94%
+9 résultats de plus
KALSHIWhen will Tesla and SpaceX merge?
- Before 2028-2.0pt63%
- Before Apr 1, 2027-1.0pt51%
- Before May 1, 2027-5.0pt49%
+8 résultats de plus
POLYMARKETWhat will OpenAI's IPO valuation be?
- $1.25T–$1.5T20%
- $1.75T–$2.0T19.1%
- $1.5T–$1.75T18.1%
+5 résultats de plus
- Volume total
- 96,6 k €
- How many states will adopt data center moratoriums in 2026?
- Conference to Win the National Championship
- Will California authorize an alternative wage or other qualifying relief from goat-herder wage and overtime obligations before Oct 1, 2026?
- Which companies will officially announce an IPO this year?
- Discord IPO Closing Market Cap
- Will another state enact a data center moratorium in 2026?
- Which Senators will vote for the Clarity Act?
- Will Wyoming create a Digital Asset Authority?
- SpaceX' Market Cap end of October 2026?
- When will the Senate vote on the Clarity Act?
Questions fréquentes
- Quelles sont les probabilités actuelles pour Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028? ?
- Manifold Markets cote Yes à 70% au 8 septembre 2026.
- Quand Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028? sera-t-il résolu ?
- Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028? doit être résolu le 31 décembre 2027.
- Comment Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028? est-il réglé ?
- Manifold Markets règle ce marché comme suit : Will BGE-102 significantly reduce hsCRP in BioAge's Phase 2 QUELL-CV trial?